Analyzing BEAT, SUPN, ADBE And RHT Stocks
Growth stock analysis BioTelemetry BioTelemetry’s (BEAT) net income has declined at a 3-year and 5-year average of 17% and 5.9% respectively. The company’s negative pre-tax margin changed from 5.5% in 2013 to 3.6% in 2017. The stock prices have beaten the diagnostics & research industry and S&P 500 between 2013 and 2017. The market […]
Total Returns and Sector Exposure for Growth Indexes—Continued
The S&P 900 Growth and S&P 900 Pure Growth indexes have three-year annualized returns of 13% and 9.7%, respectively.
Total Returns and Sector Exposure for Growth Indexes
If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT).
What Analysts Recommend for Amedisys and Peers in March 2018
Of the 11 analysts covering Amedisys in March 2018, three analysts have given the stock a “strong buy” rating.
Analyst Ratings for BioTelemetry and Its Peers in March 2018
Of the seven analysts covering BioTelemetry in March 2018, two have given it a “strong buy” rating, and five have given it a “buy.”
A Look at BioTelemetry’s Financial Performance
In fiscal 2017, BioTelemetry (BEAT) generated total revenues of $286.7 million.
Understanding BioTelemetry’s Business Strategy
BioTelemetry’s (BEAT) business strategy is to solidify its position as a leading provider of outpatient cardiac monitoring services.
Exploring BioTelemetry’s Segments
BioTelemetry’s healthcare segment contributed 81% of the company’s total revenues in fiscal 2017.